Connecticut General Statutes/Title 17b/Chapter 319ff/Section 17b-491b

CGS § 17b-491b. Reimbursement formula for drugs used to treat hemophilia A.

The maximum allowable cost paid for antihemophilic Factor VII, VIII, IX and X products under the Medicaid program shall be the actual acquisition cost as reflected on the manufacturer's invoice plus eight per cent plus the professional dispensing fee established for covered outpatient drugs.

Short History

(June Sp. Sess. P.A. 00-2, S. 35, 53; P.A. 04-76, S. 22; P.A. 11-44, S. 131; P.A. 13-234, S. 100; June Sp. Sess. P.A. 17-2, S. 200.)

Long History

History: June Sp. Sess. P.A. 00-2 effective July 1, 2000; P.A. 04-76 deleted reference to “general assistance”; P.A. 11-44 deleted “state-administered general assistance”, effective July 1, 2011; P.A. 13-234 deleted reference to ConnPACE program, effective January 1, 2014; June Sp. Sess. P.A. 17-2 deleted provision re Factor VIII pharmaceuticals, added “antihemophilic Factor VII, VIII, IX and X products”, added reference to manufacturer's invoice re acquisition cost and added “plus the professional dispensing fee established for covered outpatient drugs”, effective October 31, 2017.

PreviousCGS § 17b-491a. Prior authorization requirements for prescription drugs. Schedule for dispensing of maximum quantities of oral dosage units. Submission of schedule and revisions thereto to General Assembly.NextCGS § 17b-491c. Rebates for prescription drugs covered under state medical assistance program. Calculating of unit rebate amounts. Contracts for supplemental rebates. Pharmaceutical manufacturers' participation in program. Rebates for new drugs. Payment for medically necessary drugs.